FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer

Academic Article

Abstract

  • We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer. © 2009 Springer Science+Business Media, LLC.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Wang F; Ezell SJ; Zhang Y; Wang W; Rayburn ER; Nadkarni DH; Murugesan S; Velu SE; Zhang R
  • Start Page

  • 234
  • End Page

  • 241
  • Volume

  • 28
  • Issue

  • 3